Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates
OXFORD, UK and SAN JOSE, California, 13/06/2022 - Oxford
BioTherapeutics (OBT), a clinical stage oncology company with a pipeline
of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies,
today announced a multi-year collaboration to research, develop and
commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader
in the expanding field of ADCs for the treatment of cancer. The
companies will utilize ImmunoGen’s linker-payload technology directed to
novel targets identified via OBT's proprietary OGAP® discovery
platform. The companies will support these R&D efforts through joint
funding and by combining their respective proprietary technologies.
More info >> |